Author, year | Parameters used in studies | Data source | Age of target population | Mean age of estimation sample |
---|---|---|---|---|
From previous economic evaluations | ||||
 Skedgel et al. (2013) [21] | Disease-free to recurrence Proportion local recurrence/recurrence 'Instant' conversion from local to distant Side effects Rate of nausea |vomiting (grades 3 + 4) Rate of febrile neutropenia Rate of CHF Relative mortality risk |CHF Rate of AML/MDS Relative mortality rate |AML/MDS Relative risk of cardiotoxicity |conTZ Relative risk of cardiotoxicity |seqTZ | Recurrences from previous economic evaluations [71,72,73]. Adverse side-effects from previous trials [36, 37] | 40 years 50 years 60 years 70 years 80 + years | Patients aged > 70 years account for 16% [36] Patients aged > 60 years account for 16.3% [37] |
From randomised controlled trials | ||||
Odds reduction of 10-year mortality Disease-free to death Adjuvant Chemo CMF Adjuvant Chemo AC Adjuvant Tamoxifen Adjuvant Chemo CMF + Tamoxifen Adjuvant Chemo AC + Tamoxifen | Background non-cancer mortality from United States life tables 1997 [74]; | 45 years 65 years 75 years 85 years | Age-specific mortality from 0 to 100 years | |
 Sen et al. (2014) [20] | Disease-free to recurrence no RT Disease-free to recurrence + RT Recurrence to metastasis Metastasis to death | Clinical trial [29] | 70, 75, and 80 years |  > 70 years |
Cumulative incidence Disease-free to death Overall survival Death from 2nd cancer Disease-free to progression Ipsilateral breast tumours recurrence Contralateral breast cancer Distant metastasis Side effects Osteopenia requiring bisphosphonate Bone fracture Deep vein thrombosis Fibrosis/soft-tissue necrosis Hot flashes Arthralgia Radiation dermatitis, acute grade 3 | 70 years or older | 70 years [29]  > 65 years [30] 65.7 years [31] 57 years [32] Not reported [33] | ||
Desch et al. (1993)Â [24] | Disease-free to progression First recurrence | 60Â years 65Â years 70Â years 75Â years 80Â years | 48Â years [38] Not reported [39] |